VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
OFIXOrthofix Medical Inc.
$9.45$382M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksOFIXP/E History

OFIX logoOrthofix Medical Inc. (OFIX) P/E Ratio History

Deep Value

Trading at -4.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1999–2020

Current P/E (TTM)
-4.1x
-102% vs 5Y avg
5Y Avg P/E
228.4x
Median 96.3x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-4.1x
Min14.9xMedian96.3xMax2077.0x
TTM EPS$-1.48
Price$9.45
Earnings YieldN/A
EPS Growth (1Y)30.9%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Orthofix Medical Inc. (OFIX) trades at a price-to-earnings ratio of -4.1x, with a stock price of $9.45 and trailing twelve-month earnings per share of $-1.48.

The current P/E is 102% below its 5-year average of 228.4x. Over the past five years, OFIX's P/E has ranged from a low of 14.9x to a high of 2077.0x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, OFIX trades at a 119% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, OFIX trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our OFIX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

OFIX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-4.1vs22.1
-119%
Below Sector
vs. S&P 500
-4.1vs24.4
-117%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 31% EPS growth (1Y)

OFIX P/E vs Peers

Orthopedics, spine, and sports medicine peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
XTNT logoXTNTXtant Medical Holdings, Inc.
$62M14.7-+125%
NVAX logoNVAXNovavax, Inc.
$2B3.6Lowest-+307%
GMED logoGMEDGlobus Medical, Inc.
$11B20.20.65Best+423%Best
SYK logoSYKStryker Corporation
$118B36.62.46+8%
ZBH logoZBHZimmer Biomet Holdings, Inc.
$17B24.8--20%
HOLX logoHOLXHologic, Inc.
$17B30.5--25%
MMSI logoMMSIMerit Medical Systems, Inc.
$4B31.6-+5%
MDT logoMDTMedtronic plc
$102B22.0-+31%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

OFIX Historical P/E Data (1999–2020)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2020 Q4-$42.98$0.12358.2x+280%
FY2020 Q3Sep 30 2020$31.14$1.2025.9x-72%
FY2019 Q2Jun 30 2019$52.88$0.42127.2x+35%
FY2019 Q1Mar 31 2019$56.41$0.49114.0x+21%
FY2018 Q4Dec 31 2018$52.49$0.7173.4x-22%
FY2018 Q3Sep 30 2018$57.81$0.33172.7x+83%
FY2018 Q2Jun 30 2018$56.82$0.5996.3x+2%
FY2018 Q1Mar 31 2018$58.78$0.7578.4x-17%
FY2017 Q4Dec 31 2017$54.70$0.33165.8x+76%
FY2017 Q3Sep 30 2017$47.25$0.07675.0x+616%
FY2017 Q2Jun 30 2017$46.48$0.42110.7x+17%
FY2016 Q4Dec 31 2016$36.18$0.15241.2x+156%
FY2016 Q3Sep 30 2016$42.77$0.5183.9x-11%
FY2016 Q1-$41.52$0.5083.5x-11%
FY2013 Q3Sep 30 2013$20.77$0.012077.0x+2103%
FY2013 Q2Jun 30 2013$26.90$1.4918.1x-81%
FY2013 Q1Mar 31 2013$35.87$2.1916.4x-83%
FY2012 Q4Dec 31 2012$39.33$2.6414.9x-84%
FY2012 Q3Sep 30 2012$44.75$2.2619.8x-79%
FY2012 Q2Jun 30 2012$41.25$2.5316.3x-83%
FY2012 Q1Mar 31 2012$37.58$2.4915.1x-84%
FY2010 Q4Dec 31 2010$29.00$2.4811.7x-88%
FY2010 Q3-$31.42$2.5812.2x-87%
FY2010 Q2Jun 30 2010$32.05$2.4613.0x-86%
FY2010 Q1Mar 31 2010$36.38$2.2416.2x-83%
FY2009 Q4-$30.93$1.4221.8x-77%
FY2009 Q3Sep 30 2009$29.39$0.8435.1x-63%
FY2008 Q2Jun 30 2008$28.95$0.4170.6x-25%
FY2008 Q1Mar 31 2008$39.77$0.5079.5x-16%
FY2007 Q4Dec 31 2007$57.97$0.6687.8x-7%
FY2007 Q3Sep 30 2007$48.97$1.7328.3x-70%
FY2006 Q2Jun 30 2006$38.13$4.568.4x-91%
FY2006 Q1Mar 31 2006$39.82$4.359.2x-90%
FY2005 Q4Dec 31 2005$39.89$4.518.8x-91%
FY2005 Q3Sep 30 2005$43.60$4.679.3x-90%
FY2005 Q2-$43.04$2.3918.0x-81%
FY2005 Q1-$39.15$2.3116.9x-82%
FY2004 Q4Dec 31 2004$39.08$2.1718.0x-81%
FY2004 Q3-$34.45$2.0416.9x-82%
FY2004 Q2Jun 30 2004$42.77$1.8822.8x-76%
FY2004 Q1Mar 31 2004$49.50$1.8227.2x-71%
FY2003 Q4Dec 31 2003$48.98$1.7028.8x-69%
FY2003 Q3-$36.60$1.6721.9x-77%
FY2003 Q2Jun 30 2003$32.74$1.7119.1x-80%
FY2003 Q1Mar 31 2003$27.20$1.7215.8x-83%
FY2002 Q4-$28.14$1.7516.1x-83%
FY2002 Q3Sep 30 2002$26.46$1.6516.0x-83%
FY2002 Q2Jun 30 2002$35.15$1.5922.1x-77%
FY2002 Q1Mar 31 2002$40.33$1.4827.3x-71%
FY2001 Q2Jun 30 2001$26.83$1.3220.3x-78%
FY2001 Q1Mar 31 2001$22.56$1.2717.8x-81%
FY2000 Q4Dec 31 2000$19.13$3.275.8x-94%
FY2000 Q3Sep 30 2000$24.75$3.217.7x-92%
FY2000 Q2Jun 30 2000$17.88$3.165.7x-94%
FY2000 Q1Mar 31 2000$17.50$3.105.6x-94%
FY1999 Q4Dec 31 1999$14.31$0.9614.9x-84%
FY1999 Q3-$13.63$0.9514.3x-85%

Average P/E for displayed period: 94.3x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

27+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

OFIX — Frequently Asked Questions

Quick answers to the most common questions about buying OFIX stock.

What is OFIX's P/E ratio?

Orthofix Medical Inc. (OFIX) trailing twelve-month P/E ratio is -4.1x, based on TTM diluted EPS of $-1.48. The 5-year average P/E is 228.4x and the historical range spans 14.9x to 2077.0x.

Is OFIX stock overvalued or undervalued?

OFIX trades at -4.1x P/E, below its 5-year average of 228.4x. At the 0th percentile of its historical range (14.9x–2077.0x), the stock is priced at a discount to its own history.

Is OFIX stock expensive?

No, OFIX is not expensive on a historical basis. The current P/E of -4.1x is below the 5-year average of 228.4x and sits at the 0th percentile of its valuation range.

What is OFIX's historical P/E range?

Over the past 5 years, OFIX's P/E ratio has ranged from 14.9x to 2077.0x, with a median of 96.3x and an average of 228.4x. The current P/E of -4.1x places the stock at the 0th percentile of this range. Full historical data spans 1999–2020.

How does OFIX's P/E compare to the S&P 500?

OFIX trades at -4.1x P/E versus the S&P 500 median of 24.4x. The 117% discount to the market suggests lower growth expectations or perceived higher risk.

How does OFIX's valuation compare to Healthcare peers?

Orthofix Medical Inc. P/E of -4.1x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is OFIX's PEG ratio?

OFIX PEG ratio is N/A, based on a P/E of -4.1x and EPS growth of 30.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is OFIX's earnings yield?

OFIX earnings yield is N/A, the inverse of its -4.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

OFIX P/E Ratio History (1999–2020)

Quarterly valuation multiple from closing price and trailing EPS

Current358.2x
Period Avg228.4x
Range14.9x - 2077.0x
Change+2097%
20 quartersJun 30, 2012 - Dec 31, 2020